Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience reported a steady first quarter of 2026 operationally, with no major events but continued progress across its oncology pipeline and platforms. The company highlighted new and updated mitazalimab data from the OPTIMIZE 1 study presented at a key gastrointestinal cancer meeting and additional scientific visibility via an investigator-initiated trial accepted for presentation at a major cancer research conference.
Partnered asset HLX22 advanced as Henlius dosed the first patient in a Phase 2/3 trial in recurrent breast cancer, while Alligator strengthened intellectual property protection around its RUBY bispecific antibody technology, supporting future pipeline and partnering prospects. On the financial side, the firm remained loss-making at the operating level but reported a small profit for the period and bolstered liquidity through the exercise of TO 14 warrants, while management’s intention to subscribe pro rata and proposed new board appointments underscored an effort to align governance and capital structure with long-term strategic goals.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology company focused on developing antibody-based immunotherapies for cancer, including the CD40 agonist mitazalimab and bispecific antibody technologies such as its RUBY platform. The company operates primarily in early- and mid-stage clinical development, with a strategy built around partnerships and out-licensing to advance programs into late-stage trials.
Average Trading Volume: 16,977,314
Technical Sentiment Signal: Sell
Current Market Cap: SEK113.3M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.